All Drug Discovery articles – Page 6
-
NewsNew kidney water regulation mechanism could improve polycystic kidney disease treatment
Scientists at Mayo Clinic have discovered a previously unknown mechanism by which kidneys regulate water balance, offering new therapeutic possibilities for polycystic kidney disease patients experiencing severe side effects from current treatments.
-
NewsCopper drug Cu(ATSM) reduces Alzheimer’s proteins by 42 percent in preclinical study
A copper-delivering compound has demonstrated the ability to restore blood-brain barrier clearance mechanisms, reducing amyloid-beta accumulation by 42 percent and improving spatial learning by 44 percent in Alzheimer’s disease models, according to research published in ACS Chemical Neuroscience.
-
ReportContext is everything: how spatial biology is changing our understanding of disease
Discover how spatial biology is revealing disease mechanisms with implications for biomarkers, immunotherapy and drug development.
-
ArticlePomegranate-derived compound shows therapeutic potential in heart disease
Researchers at Cardiff University have identified urolithin A – a compound produced by gut bacteria during the metabolism of substances found in pomegranates – as a new approach for treating cardiovascular disease.
-
NewsAI-designed miniproteins target GPCRs in drug discovery
GPCRs account for a significant proportion of approved drug targets, yet selectively controlling their activity remains a major challenge. Researchers have now used AI-assisted protein design to create miniproteins capable of activating or inhibiting these receptors, providing an alternative strategy for targeting this important class of membrane proteins.
-
ArticleAACR 2026 part two: integrating AI, spatial biology and next-gen therapeutics
In part two of our AACR 2026 coverage, industry leaders were focussed on how the field is no longer constrained by data generation or molecular design, but by the challenge of connecting systems, standardising workflows and ensuring biological insights.
-
ReportAI in Drug Discovery: Progress, Limits and What Comes Next
AI has attracted enormous investment across drug discovery, but major questions still remain around validation, reproducibility and real-world application. In our latest Beyond the Lab report, experts discuss where the technology is starting to influence discovery workflows – and where limitations continue to slow adoption.
-
NewsELRIG announces keynote speakers for Drug Discovery 2026 conference in London
ELRIG has announced its keynote speaker programme for Drug Discovery 2026, with LifeArc’s Dr Sam Barrell CBE delivering the opening address.
-
ArticleFrom chemist to AI agent builder: inside the rise of agentic AI in drug discovery
Dr Raminderpal Singh speaks with Dr Srijit Seal about why specialised AI agents are outperforming general-purpose models in drug discovery and what a new consortium paper shows about their use in practice.
-
NewsPlatinum-antibody conjugates enhance immunotherapy while reducing chemotherapy toxicity
A novel platinum(IV)-antibody conjugate platform delivers low-dose chemotherapy directly to tumours, upregulating MHC-I expression and enhancing anti-PD-1 responses while minimising systemic exposure. The approach addresses immune evasion mechanisms that limit checkpoint inhibitor efficacy.
-
NewsParse Biosciences and bit.bio map transcription factor-driven cell identity
Parse Biosciences and bit.bio have formed an alliance to map transcription factor-driven cell identity using single cell sequencing and causal transcriptomics.
-
ArticleMachine learning identifies biological signals linked to emotional hunger
Researchers at Phenomix Sciences are using machine learning and genetic risk scoring to investigate emotional hunger, an obesity phenotype linked to emotional and reward-driven eating behaviours. Dr Timothy O’Connor discusses how the approach could improve patient stratification, obesity research and treatment selection.
-
NewsGinkgo Bioworks launches ADME-One platform for early-stage screening
Ginkgo Bioworks has launched ADME-One, an integrated platform combining high-throughput ADME testing with AI-powered human pharmacokinetic projections.
-
NewsAI platform identifies novel gp130 inhibitor for colorectal cancer
An AI-assisted drug discovery platform using transfer learning has identified a promising gp130 inhibitor for colorectal cancer.
-
NewsAI identifies 23 antiviral candidates for Bundibugyo Ebola strain
US researchers have deployed artificial intelligence and molecular docking software to identify 23 antiviral compounds with potential activity against Bundibugyo Ebolavirus, as the rare strain continues to spread in the Democratic Republic of Congo with a fatality rate approaching 40 percent.
-
ArticleBeyond tangles: why soluble intracellular tau should guide drug discovery
Tau tangles are a hallmark of Alzheimer’s disease and related disorders, but evidence suggests the real damage may come from rare, soluble tau species inside neurons. Targeting these hidden drivers of circuit dysfunction could be key to restoring memory and cognition.
-
ArticleWhy AI models need patient data to deliver in drug discovery
Despite rapid advances in AI, many drug discovery models still struggle to translate computational predictions into clinical outcomes. Thomas Clozel explains how Owkin is training AI on large-scale patient-derived data while integrating experimental and clinical validation directly into model development.
-
NewsCholesterol trafficking disruption targets TP53-mutant cancers
Scientists have identified a mechanism to starve aggressive cancers by blocking cholesterol transport within tumour cells, offering a targeted approach for malignancies carrying TP53 mutations, present in half of all cancers.
-
ArticleTurning GWAS signals into drug targets with scalable CRISPR
Genome-wide association studies have linked thousands of genetic variants to disease, yet most remain disconnected from drug-relevant biology. Neville Sanjana, Professor at New York University and Core Faculty Member at the New York Genome Center, explains how scalable CRISPR screens systematically link noncoding variants to causal genes and therapeutic targets.
-
NewsPERM1 protein linked to heart recovery in LVAD patients
A newly identified protein may explain why some failing hearts recover function following mechanical support while others do not.